Overview

A Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's Disease

Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Objective of this study is to investigate the safety, pharmacokinetics and efficacy of KDT-3594 in patients with early Parkinson's disease without a concomitant medication of L-dopa.
Phase:
Phase 2
Details
Lead Sponsor:
Kissei Pharmaceutical Co., Ltd.